Functional electrical stimulation (FES) produces beneficial effects in the treatment of patients with chronic heart failure (CHF), but studies carried out in these patients show small sample sizes and conflicting results. The aim of this meta-analysis was to systematically review the effect of treatment with FES compared with conventional aerobic exercise training (CA) or control group in patients with CHF. The search strategy included MEDLINE, LILACS, Physiotherapy Evidence Database and Cochrane Library. Randomized trials comparing FES versus CA or control group in the treatment of patients with CHF were included. Two reviewers independently extracted the data. Main analysis used a fixed-effects model. The search retrieved 794 articles, from which seven studies were included. Treatment with FES provided a smaller gain in peak VO2 compared with CA {-0.74 ml/kg per min [95% confidence interval (CI): -1.38 to -0.10]}. There was no difference in the muscle strength [-0.33 Nm (95% CI: -4.56 to 3.90)] and in the distance of the 6-min walk test [2.73 m (95% CI: -15.39 to 20.85)] on comparing FES with CA. An increase in peak VO2 of 2.78 ml/kg per min (95% CI: 1.44-4.13) was observed in FES versus the control group. Treatment with FES provides a similar gain in the distance of the 6-min walk test and in the muscle strength when compared with CA, but a small gain in the peak VO2. An increase in the peak VO2 can be obtained with FES as compared with the control group. Thus, FES may be an alternative in relation with CA for patients with CHF and with those who are unable to perform this kind of exercise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/HJR.0b013e328339b5a2 | DOI Listing |
Allergol Immunopathol (Madr)
January 2025
Research Department, Fundación Cardioinfantil, Bogotá, Colombia.
Background: Asthma, a chronic inflammatory lung disease, is one of the leading causes of disability, demands on health resources, and poor quality of life. It is necessary to identify asthma-related risk factors to reduce the presence and development of symptoms.
Objective: This study aimed to explore the association of multiple possible factors with asthma symptoms in two subpopulations, children, adolescents, and adults, in six cities in Colombia.
Allergol Immunopathol (Madr)
January 2025
Regional Center for Allergy and Clinical Immunology, University Hospital "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico;
Objective: Allergic rhinitis (AR) is highly prevalent worldwide. Good patient adherence ensures successful treatment. This study aimed to identify the association between the intranasal aerosol technique and symptom improvement.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Biological Sciences, University of Extremadura, Spain.
Objective: Asthma is an inflammatory airway condition and the most common chronic disease in children. However, there is a lack of biological markers for asthma, especially in children. This study aimed to analyze the changes in periostin levels in children with uncontrolled asthma after 12 months of optimized management.
View Article and Find Full Text PDFPsychol Trauma
January 2025
Department of Psychiatry, Columbia University Irving Medical Center.
Objective: Survivors of childhood maltreatment (CM) often experience self-stigma, the internalization of negative attitudes such as shame, self-blame, and a reluctance to disclose their experiences. These self-perceptions pose a significant barrier to treatment-seeking and may exacerbate psychiatric distress. Prior research indicates that social contact-based interventions are effective in reducing stigma, but no study to date has examined their impact on self-stigma and increasing openness to treatment-seeking among CM survivors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!